Improvement In Skin Condition Research Articles

Skin health promoting effects of a proprietary nutraceutical ingredient (SesZen-BioTM): a placebo controlled, double-blind, and randomized clinical study

Background: This study evaluated the skin health benefits of SesZen-BioTM, a 0.5% natural biotin supplement derived from Sesbania grandiflora, previously linked to hair growth, in healthy adults aged 30-55 with mild skin ageing. Methods: In a single-center, double-blind, placebo-controlled trial, participants between ages 30-55 years with mild skin ageing received either SesZen-BioTM or a placebo, with assessments conducted on days 0, 28, and 56. Parameters measured included facial wrinkles, fine lines, skin elasticity, hydration, skin barrier function and overall skin health. Results: Significant reduction (p<0.01) in crow’s feet area by 27.11% (day 28) and 48.14% (day 56) and 17.95% and 51.17% reduction in fines lines were observed in the treatment group as compared to 12.1% reduction for placebo group at day 56. Physician global assessment (PGA) scores showed improvement in skin condition by 14.07% (day 28) and 20.58% (day 56) for SesZen-BioTM treatment group. The facial skin tone assessment described by individual typology angle (ITA) showed lighter skin tone by 30.55% (day 28) and 58.23% (day 56) (p<0.01). Treatment group showed decrease in retraction time for skin elasticity on day 56, decreased skin roughness and increased skin hydration. Both groups showed decreased transepidermal water loss (TEWL) on both visits (days 28 and 56) as compared to baselines (p<0.01). The placebo group showed no improvement in PGA score, skin tone lightness (L*) and ITA score, skin hydration, or skin elasticity. Conclusions: SesZen-BioTM appears to effectively promote skin health, reducing fine lines and improving skin tone, elasticity, and hydration, suggesting a viable strategy for combating skin aging and enhancing overall skin appearance.

Halobacteria Formula Improvement of Skin Care-A Randomized, Double-Blind, Placebo-Controlled Clinical Study.

Halobacteria trueperi, an extremophilic microorganism thriving in high-salt environments, produces extracellular polysaccharides with potential anti-inflammatory and anti-aging properties. However, its clinical efficacy in skin improvement remains unclear. This study focuses on H. trueperi TCI66207, isolated from the Pacific Ocean at a depth of 662 m near Hualien, and its potential to enhance skin parameters, aiming to develop a novel functional formulation for pharmaceutical and cosmetic use. This sudy aims to evaluate the clinical efficacy of H. trueperi TCI66207 on various skin parameters and its potential for developing new functional cosmetic formulations. A total of 40 subjects were recruited and randomly divided into two groups: the test group applied a serum containing H. trueperi TCI66207, while the placebo group used a basic serum. Subjects were instructed to apply the serum twice daily for 4 weeks. Skin parameters, including moisture, brightness, elasticity, pigmentation (spots and UV spots), texture, wrinkles, pores, and collagen density, were assessed before and after the 4-week application period. After 4 weeks of using the H. trueperi TCI66207 serum, significant improvements were observed in all measured skin parameters compared to baseline, with notable enhancements in moisture, brightness, elasticity, texture, and collagen density, along with reductions in wrinkles, spots, and pore size. Halobacteria trueperi TCI66207 serum demonstrates a clear ability to improve skin conditions and delay signs of aging, making it a promising candidate for the development of new cosmetic formulations with potent anti-aging and skin-rejuvenating properties.

Hyaluronic acid-solid lipid nano transporter serum preparation for enhancing topical tretinoin delivery: skin safety study and visual assessment of skin.

The use of nanosized particles is becoming more popular for the topical treatment of skin conditions. In this research work, we created and investigated the effects of solid lipid nanoparticles (SLN) containing hyaluronic acid and tretinoin. Solvent emulsification diffusion method was used to prepare the SLN formulation and characterized for their physicochemical properties. Fourier transform infrared spectroscopy was used to confirm that hyaluronic acid and tretinoin were incorporated in the SLN. Furthermore, X-ray diffractogram, thermal analysis including DSC and TGA and in vitro dissolution, permeation tests were also performed along with microbial assessment. Clinical studies in human were performed to evaluate the effect of the SLN on skin wrinkles. The SLN was 750 ± 31.29nm in size, with a zeta potential of 13.07 ± 0.75mV and a narrow polydispersity index of 0.24 ± 0.12. The entrapment efficiency of tretinoin was found to be 90.07 4.79%. Clinical studies in healthy human volunteers demonstrated that 90% of the tested individuals had improved skin conditions (reduction in wrinkles), by at least one grade after 4weeks of treatment. Regarding the development on SLN, it was found that the internal phase concentration did not considerably affect the physicochemical and microbiological properties. Therefore, Hyaluronic acid has potential for the development of SLN applicable to cosmetic formulations, especially for skin. These findings show that the developed SLN have potential for use as cosmetics in the future.

Strategies for Differential Diagnosis and Management of Ichthyosis in Newborns

Congenital ichthyosis represents agroup of heterogeneous inherited skin diseases characterized by generalized keratinization disorder in the form of hyperkeratosis, caused by abnormalities in epidermal differentiation. The neonatal period is crucial for patients with ichthyosis due to the risk of developing complications, comorbidities, and fatal outcomes. Most complications arise from impaired skin barrier function. This article discusses the manifestations of ichthyosis in newborns, describes risks and complications, and suggests strategies for monitoring and treating patients. Purpose of the study: to present contemporary data on differential diagnosis and treatment strategies for newborn patients with congenital ichthyosis. Materials and Methods: review of Russian and international sources dedicated to the etiology, diagnosis, and treatment of ichthyosis was conducted. Results: Differential diagnosis of ichthyosis in the neonatal period is acrucial task, hence the most life-threatening subtypes are considered. The most severe progression with ahigh risk of fatal outcomes is characteristic of Harlequin ichthyosis. Collodion baby presents with less pronounced symptoms, is not afinal diagnosis, and may later develop clinical manifestations typical of ichthyosiform erythroderma, lamellar ichthyosis, or self-resolving congenital ichthyosis. Netherton syndrome is characterized by acombination of congenital ichthyosis with structural abnormalities of the hair shaft and apropensity for atopy. Epidermolytic ichthyosis, accompanied by the formation of blisters and erosions on the skin, requires differential diagnosis not only with other forms of ichthyosis but also with bullous epidermolysis, staphylococcal scalded skin syndrome, and toxic epidermal necrolysis. Every newborn with described manifestations requires support from amultidisciplinary team of specialists and timely therapeutic and diagnostic measures aimed at preventing the development of complications and deterioration of the patient’s condition. Conclusion: An analysis of global literature data and the practical experience of the authors indicate the complexities of differential diagnosis of ichthyosis forms in the neonatal period. To improve skin condition, prevent infectious complications, and correct electrolyte and respiratory disturbances, symptomatic treatment should begin before adefinitive diagnosis is established.

Isolation, genomic analysis and functional characterization of Enterococcus rotai CMTB-CA6, a putative probiotic strain isolated from a medicinal plant Centella asiatica.

Probiotics and their derivatives offer significant health benefits by supporting digestive health, boosting the immune system, and regulating the microbiomes not only of the internal gastrointestinal track but also of the skin. To be effective, probiotics and their derivatives must exhibit robust antimicrobial activity, resilience to adverse conditions, and colonization capabilities in host tissues. As an alternative to animal-derived probiotics, plant-derived lactic acid bacteria (LAB) present promising advantages, including enhanced diversity and tolerance to challenging environments. Our study focuses on exploring the potential of plant-derived LAB, particularly from the medicinal plant Centella asiatica, in improving skin conditions. Through a bacterial isolation procedure from C. asiatica leaves, Enterococcus rotai CMTB-CA6 was identified via 16S rRNA sequencing, whole genome sequencing, and bioinformatic analyses. Based on genomic analysis, antimicrobial-resistance and virulence genes were not detected. Additionally, the potential functions of E. rotai CMTB-CA6 were characterized by its lysates' ability to regulate skin microbes, such as stimulating the growth of Staphylococcus epidermidis while inhibiting that of Cutibacterium acnes, to restore the viability of human dermal fibroblasts under inflammatory conditions, and to demonstrate effective antioxidant activities both in a cell-free system and in human dermal fibroblasts. Our investigation revealed the efficacy of E. rotai CMTB-CA6 lysates in improving skin conditions, suggesting its potential use as a probiotic-derived agent for skin care products. Considering the ecological relationship between plant-inhabited bacteria and their host plants, we suggest that the utilization of E. rotai CMTB-CA6 strain for fermenting its host plant, C. asiatica, could be a novel approach to efficiently enriching bioactive molecules for human health benefits.

Real-World Experience Using a Multi-Modality System using Intense Pulsed Light, Radiofrequency Microneedling, High-Intensity Focused Ultrasound, or Thermal Radiofrequency, 808, HIFU for Skin Rejuvenation Treatment.

Medical aesthetic procedures for facial rejuvenation with laser and energy-based devices (EBDs) are rapidly increasing. The following cases highlight real-life experience using a multi-modality system with various handpieces that combine intense pulsed light (IPL), laser hair removal (808 diode), high-intensity focused ultrasound (HIFU), radiofrequency microneedling (RFM), and thermal radiofrequency (RF) for antiaging and rejuvenation treatment. Laser and RFM treatments may improve skin conditions by inducing cutaneous changes that remodel the skin matrix. Six physicians who treat patients for skin rejuvenation reported on clinical cases from their practice using a multi-modality system with various handpieces. During the meeting, the advisors discussed 15 cases and agreed to select seven patients with different ages and skin phototypes receiving various treatments for photodamage of the face, neck, and décolleté. The advisors discussed why they selected the case, previous treatment, type of treatment, results, and clinical pearls. Sharing best practices in medical aesthetics using combination treatments on a single multi-modality energy-based device such as laser and MRF for facial, neck, and chest skin may support healthcare providers treating patients for skin rejuvenation to improve clinical outcomes.

Role of skin circadian rhythm and the effect of day and night cream: a survey on Indian dermatologists’ and cosmetologists’ views and patient experiences

Background: The skin plays different functions during the day and night to adapt to the changing environments. Various specialized creams are available to meet these skincare needs. The present study was conducted to explore the perspective of Indian dermatologists and cosmetologists on skin’s circadian rhythm and assess the effectiveness of a particular day and night cream formulation. Methods: A non-interventional, questionnaire-based study was conducted as part of a survey series on multiple dermatology products across India. Every month, a product-specific survey link was released to these registered doctors, and each doctor could take up to 10 surveys for a maximum of two products. A total of 379 healthcare professionals (HCPs) took the survey on the day and night cream and reported experiences of 2085 patients regarding the use of these products. Results: The doctors believed that for majority of the patients (1997, 97%), required day and night cream to maintain their skin’s circadian rhythm. Most patients (1440, 70%) were compliant with day and night care cream regimens. Most patients (966, 47%) were highly satisfied with the use of day and night cream, with majority of the patients (1028, 49.4%) experiencing considerable reduction in dark spots and uneven skin tone. Most patients (971, 47%) felt that the application of day and night cream left their skin moisturized and rejuvenated. Conclusions: The use of day and night cream improved skin condition and hydration, addressing circadian rhythm imbalance. Indian HCPs understand the impact of skin circadian rhythm imbalance and promote a comprehensive skincare regimen to patients.

Phenylalanine Butyramide: A Butyrate Derivative as a Novel Inhibitor of Tyrosinase.

Metabolites resulting from the bacterial fermentation of dietary fibers, such as short-chain fatty acids, especially butyrate, play important roles in maintaining gut health and regulating various biological effects in the skin. However, butyrate is underutilized due to its unpleasant odor. To circumvent this organoleptic unfavorable property, phenylalanine butyramide (PBA), a butyrate precursor, has been synthesized and is currently available on the market. We evaluated the inhibition of mushroom tyrosinase by butyrate and PBA through in vitro assays, finding IC50 values of 34.7 mM and 120.3 mM, respectively. Docking calculations using a homology model of human tyrosinase identified a putative binding mode of PBA into the catalytic site. The anti-aging and anti-spot efficacy of topical PBA was evaluated in a randomized, double-blind, parallel-arm, placebo-controlled clinical trial involving 43 women affected by photo-damage. The results of this study showed that PBA significantly improved skin conditions compared to the placebo and was well tolerated. Specifically, PBA demonstrated strong skin depigmenting activity on both UV and brown spots (UV: -12.7% and -9.9%, Bs: -20.8% and -17.7% after 15 and 30 days, respectively, p < 0.001). Moreover, PBA brightened and lightened the skin (ITA°: +12% and 13% after 15 and 30 days, respectively, p < 0.001). Finally, PBA significantly improved skin elasticity (Ua/Uf: +12.4% and +32.3% after 15 and 30 days, respectively, p < 0.001) and firmness (Uf: -3.2% and -14.9% after 15 and 30 days, respectively, p < 0.01).

Grape Seed Extract Supplement With Nicotinamide, Vitamin C and Vitamin E Improved Skin Condition in Human

Grape Seed Extract Supplement With Nicotinamide, Vitamin C and Vitamin E Improved Skin Condition in Human

Metformin Therapy for Acne Vulgaris: A Meta-Analysis.

Acne vulgaris is a common disease, which occurs in adolescents as well as adults and has a significant influence on the patient's quality of life (QoL) in every aspect. Due to resistance to standard therapies, it has become necessary to prospect for new treatment strategies. It is important to highlight that the diagnosis and treatment of the underlying cause of acne such as metabolic and hormonal disorders may significantly improve the effectiveness of acne treatment. The correlation between Insulin Resistance (IR) and acne has been proven. Both disorders share many common occurrence factors and activation pathways. Metformin, an antihyperglycemic agent, seems to be a possible therapy option, not only because of its insulin sensitizing ability but also via plenty of additional effects of this medicine. While the efficiency of metformin therapy in patients with acne and Polycystic Ovary Syndrome (PCOS) is well explored, it is still necessary to evaluate it in patients without any endocrinopathies. This meta-analysis aimed to estimate the effectiveness of oral metformin as a monotherapy in acne patients without PCOS or other endocrinopathies. Study selection was performed with included criteria such as no PCOS and other endocrinopathies diagnosed, oral administration of metformin, and metformin in monotherapy. Selected studies contained comparisons in the Global Acne Grading System (GAGS) before and after metformin therapy. Statistical analysis detected significant improvement in skin condition after treatment with metformin.

TREATMENT OF SCABIOSIS AND TOXOCARIOSIS IN DOMESTIC CAT

Skin and digestive diseases are the most common problems encountered in cats. A six-month-old domestic cat with a body weight of 1.42 kg experienced problems with the skin and digestive system at the same time. Cases of cats complain that they often scratch and excrete worms when defecating, the feces are yellow and have a paste-like consistency. This research aims to determine the disease agent and intensity of infection that attacks cats so that appropriate treatment can be provided. On physical examination, alopecia, hyperkeratosis, crusting and scales were found on the head, bilateral ears, neck and elbow area. Supporting examinations carried out were skin examination using skin scraping, trichogram, cytological examination using the tape acetate method and otic swab with diffquick staining as well as fecal examination using the floating method and counting worm eggs using the Mc Master method. The diagnosis is confirmed based on the history, physical examination, and examination with results of scabiosis and toxocaryosis. The causative therapy used in this case was ivermectin (Ivomec®) injection at a dose of 300μg/kg BW subcutaneously given three times on days 0, 7 and 14 and pyrantel pamoate (Combantrin®) therapy at a dose of 25 mg/kg BW orally. Symptomatic therapy uses intramuscular injection of diphenhydramine HCl (2 mg/kg BW) and (chlorpeniramine maleate®) at a dose of 2 mg/head given 2x¼ orally given for three days, followed by supportive therapy given multivitamins and minerals (Caviplex®) given once a day orally for seven days. Topical therapy is given with sulfur soap to bathe cats at least once a week. The cat showed good progress starting from the third day, the level of pruritus decreased, then on the fourth day the cat did not expel worms from the anus and the stomach did not look as enlarged as when it was first examined, and on the sixth day it started to show hair growth, alopecia, crusting and hyperkeratosis began to decrease. After administering ivermectin the second time, the cat's case began to improve with the level of pruritus decreasing and the hair slowly growing. After the third injection, namely on the fourteenth day, the cat named Bolu was returned to its owner with improved skin condition and no longer scratching. Based on the history, physical examination and laboratory examination, the cat was given therapy by administering antihistamines, antiparasitics, worm medicine, as well as support by administering vitamins and topical use of sulfur soap. It is important for cat owners to consistently bathe their cats and give them regular deworming medication to prevent recurrent infections.

The therapeutic effects of ADSCs on photoaging of skin induced by UVB irradiation.

Skin photoaging affects appearance and is associated with a variety of skin diseases, even skin cancer. Therefore, the prevention and treatment of skin photoaging is very important. However, there is a lack of effective evaluation methods, so it is an urgent problem to explore a comprehensive, non-invasive and in vivo evaluation method. Adipose-derived mesenchymal stem cells (ADSCs) are widely used to improve skin conditions as easier to obtain and positive effects. Recently, as the development of ultrasound technology, skin ultrasound has been widely used. Changes in skin layer and structure can be observed by high-frequency ultrasound (HFUS). In addition, Shear wave elastography (SWE) technology can be used to monitor the change of skin hardness. However, it is necessary to further explore the ultrasound parameters in interpreting histological changes. We simulate the progression and treatment process of human skin photoaging by using UVB-induced nude mice skin photoaging model and ADSCs injection. The analysis of the degree and therapeutic effect of skin photoaging was conducted by HFUS, SWE and to verify with histopathology. Our study aims to clarify the value of HFUS combined SWE techniques in evaluating the degree and therapeutic efficacy of skin photoaging, which provides theoretical basis for diagnosis and treatment evaluation systems.

The Efficacy of a Cosmetic Preparation Containing Sheep Colostrum on Mature Skin: A Randomized Placebo-Controlled Double-Blind Study

Colostrum, the first milk produced by mammals, is rich in various bioactive components that provide numerous health benefits to newborns, such as growth factors, hormones, immunoglobulins, cytokines, and enzymes. Topical application of bovine or equine colostrum has been found to improve regeneration, accelerate cutaneous wound healing, and have moisturizing, protective, and anti-aging properties. The aim of this study was to examine the effect of a cosmetic preparation containing sheep colostrum on skin with signs of aging in mature women. Fifty-two women, aged 40–70, were randomized into two groups to receive either colostrum or placebo cream. The participants applied the cream for eight weeks. Skin hydration, TEWL, sebum, erythema, and tone were measured using a standardized Courage + Khazaka electronic GmbH Multi Probe Adapter; skin elasticity was measured with a cutometer, and images were taken by FotoMedicus. The treatment increased skin moisture, reduced TEWL, and improved skin firmness. These findings were confirmed by the subjective survey. The participants reported, inter alia, improved skin softness and less redness and hypersensitivity. Sheep colostrum cream was more effective at improving skin conditions than placebo cream. Colostrum creams can improve certain aspects of skin quality, especially the hydrolipid barrier, and overall rejuvenation.

High mobility group box 1 cytokine targeted topical delivery of resveratrol embedded nanoemulgel for the management of atopic dermatitis.

Resveratrol is a polyphenolic compound showing anti-inflammatory activity by inhibition of high mobility group box 1 cytokine responsible for the activation of nuclear factor-κB pathway in atopic dermatitis. To evaluate the efficacy of resveratrol through topical route we have developed resveratrol-loaded nanoemulgel for the effective management of atopic dermatitis in mice model. The resveratrol-loaded nanoemulsion (0.5%, 0.75% and 1% w/w) was optimized by spontaneous nano-emulsification. The optimized resveratrol-loaded nanoemulsions showed average globule size in the 180-230nm range and found to be monodispersed. The resveratrol nanoemulgel was prepared with a SEPINEO™ P 600 gel base and propylene glycol. Ex vivo permeation and retention study resulted in significantly higher skin retention of resveratrol from resveratrol-loaded nanoemulgel than free resveratrol-loaded gel. Preclinical efficacy of resveratrol nanoemulgel displayed promising therapeutic outcomes where, western blotting of skin tissues disclosed a significant reduction in the relative expression of high mobility group box 1, the receptor for advanced glycation end products, toll-like receptor-4 and phosphorylated nuclear factor-κB. Further, real-time polymerase chain reaction also disclosed a significant reduction in pro-inflammatory cytokines such as thymic stromal lymphopoietin, interleukin-4, interleukin-13, interleukin-31, tumor necrosis factor-α and interleukin-6. The histopathological examination of skin sections showed improvement in the skin condition. Collectively, the findings from our study showcased the significant improvement in the atopic dermatitis skin condition in mice model after topical application of resveratrol loaded nanoemulgel.

Ultrasonographic Picture Of The Skin And Subcutaneous Tissue In The Treatment Of Cellulite Using The Compressive Microvibration®

In recent years, the demand for non-invasive methodologies in aesthetic medicine for treating localized adiposity, cellulite, and sagging skin has increased significantly, particularly the demand for massage techniques with mechanical vibrations. The aim of the present study is to evaluate the effectiveness of Compressive Microvibration® in reducing the expression of cellulite and improving skin conditions in women of different ages under ultrasound control during 60 days of observation. A prospective, single-center, nonrandomized study enrolled 27 women with mild to moderate gynoid lipodystrophy, aged 40 to 69 years, who have been subject to twelve sessions of Compressive Microvibration® (Endospheres®). A specialized high-resolution digital ultrasound system, the DUB SkinScanner (tpm GmbH, Germany), has been used to visualize the skin. Also, the sample anthropometric parameters have been measured, the body mass index has been calculated, and photographs have been taken. In the patients included in the study, in all age groups, after complete treatment of Endospheres®, a decrease in BM has been noted, with a reduction of the bitrochanteric and hip circumference. An improvement in the morphological topography of the skin in terms of regularization of skin irregularities, leveling of reliefs, reduction of depressions, and increase in skin elasticity and density has also been recorded. After a cycle of therapy on the anterior surface of the abdomen and the thigh anterior and posterior surfaces, the scannograms revealed a decrease in the thickness of the epidermis at various levels, the resolution of the phenomenon of hyperkeratosis, a compaction of the dermis, and an increase in its homogeneity and echogenicity. The effect obtained was still present during a control examination two months after the conclusion of the treatment. The analysis of the dynamics of ultrasound criteria demonstrated the effectiveness of the Compressive Microvibration® in women with mild to moderate gynoid lipodystrophy to improve their skin conditions and maintain the obtained effect for 2 months of observation without unwanted side complications.

Safety and efficacy of whole-body chlorhexidine gluconate cleansing with or without emollient in hospitalised neonates (NeoCHG): a multicentre, randomised, open-label, factorial pilot trial

Healthcare-associated infections account for substantial neonatal in-hospital mortality. Chlorhexidine gluconate (CHG) whole body skin application could reduce sepsis by lowering bacterial colonisation density, although safety and optimal application regimen is unclear. Emollients, including sunflower oil, may independently improve skin condition, thereby reducing sepsis. We aimed to inform which concentration and frequency of CHG, with or without emollient, would best balance safety and the surrogate marker of efficacy of reduction in bacterial colonisation, to be taken forward in a future pragmatic trial evaluating clinical outcomes of sepsis and mortality. In this multicentre, randomised, open-label, factorial pilot trial, neonates in two hospital sites (South Africa, Bangladesh) aged 1-6 days with gestational age ≥ 28 weeks and birthweight 1000-1999 g were randomly assigned in a factorial design stratified by site to three different concentrations of CHG (0.5%, 1%, and 2%), with or without emollient (sunflower oil) applied on working days vs alternate working days. A control arm received neither product. Caregivers were unblinded although laboratory staff were blinded to randomisation Co-primary outcomes were safety (change in neonatal skin condition score incorporating dryness, erythema, and skin breakdown) and efficacy in reducing bacterial colonisation density (change in total skin bacterial log10CFU from randomisation to day-3 and day-8). The trial is registered at the ISRCTN registry, ISRCTN69836999. Between Apr 12 2021 and Jan 18 2022, 208 infants were randomised and 198 were included in the final analysis. Skin condition scores were low with mean 0.1 (sd=0.3; N=208) at baseline, 0.1 (sd=0.3; N=199) at day 3 and 0.1 (sd=0.3; N=189) at day 8, with no evidence of differences between concentration (1% CHG vs 0.5% estimate=-0.3, 95% CI= (-1.2, 0.6), p=0.55. 2% CHG vs 0.5% CHG estimate=0.5 (-0.4, 1.4), p=0.30), increasing frequency (estimate=-0.4; 95% CI= (-1.1, 0.4), p=0.33), emollient (estimate=-0.5, (-1.2, 0.3), p=0.23) or with control (estimate=-0.9, (-2.3, 0.4), p=0.18). Mean log10CFU was 4.9 (sd=3.0; N=208) at baseline, 6.3 (sd=3.1; N=198) at day 3 and 8.4 (sd=2.6; N=183) with no evidence of differences between concentration (1% CHG vs 0.5% estimate=-0.4; 95% CI= (-1.1, 0.23); p=0.23. 2% CHG vs 0.5% CHG estimate=0.0 (-0.6, 0.6), p=0.96), with increasing frequency (estimate=-0.4; 95% CI= (-0.9, 0.2); p=0.17), with emollient (estimate=0.4, 95% CI= (-0.2, 0.9); p=0.18) or with control (estimate=-0.2, 95% CI= (-1.3, 0.9); p=0.73). By day-8, overall 158/183 (86%) of neonates were colonised with Enterobacterales, and 72/183 (39%) and 69/183 (9%) with Klebsiella spp resistant to third-generation cephalosporin and carbapenems, respectively. There were no CHG-related SAEs, emollient-related SAEs, grade 3 or 4 skin scores or grade 3 or 4 hypothermias. In this pilot trial of CHG with or without sunflower oil, no safety issues were identified, and further trials examining clinical outcomes are warranted. The relatively late start application of emollient, at a mean of 3.8 days of life, may have reduced the impact of the intervention although no subgroup effects were detected. There was no clear evidence in favour of a specific concentration of chlorhexidine, and there was rapid colonisation with Enterobacterales with frequent antimicrobial resistance, regardless of skin application regimen. The MRC Joint Applied Global Health award, the Global Antibiotic Research and Development Partnership (GARDP), MRC Clinical Trials Unit core funding (UKRI) and St. George's, University of London.

Magnesium of Dead Sea Salts as a Key Factor for the Treatment of Seborrheic and Atopic Dermatitis: A Case Report

Background: Seborrheic and atopic dermatitis are common and chronic inflammatory skin diseases. Conventional treatments are often ineffective and can have significant side effects. Magnesium dead sea salt has a high concentration of magnesium, and previous research shows its potential to help improve skin conditions.&#x0D; Case presentation: Patients with chronic seborrheic and atopic dermatitis were treated with topical 5% dead sea salt magnesium for 4 days. Patients experienced significant improvement in their symptoms.&#x0D; Conclusion. Dead Sea salt magnesium can be a safe and effective treatment for seborrheic and atopic dermatitis.

Improvement of postural control in the frail older adults through foot care: A pre- and post-intervention study

Frailty in older adults often leads to foot issues, increasing fall-related fracture risk. Mechanoreceptors, the pressure receptors in the foot sole, are pivotal for postural control. Foot problems can impair mechanoreceptor function, compromising balance. This study aimed to examine the effect of foot care on postural control in frail older adults. Forty-eight participants underwent a five-month monthly foot care intervention. Measurements were taken before and after this intervention. Participants stood for 45 s in a static, open-eyed position on a stabilometer. Center-of-pressure (CoP) analysis included total trajectory length, integrated triangle area, rectangular area, and range of motion in anterior–posterior and medio-lateral directions. Results indicated that foot care significantly increased toe ground contact area by 1.3 times and improved anterior–posterior motion control during static standing. Enhanced postural control resulted from improved skin condition due to foot care that intensified mechanoreceptor signal input and improved postural control output. These findings underscore the potential for reducing fracture risks in older adults through proactive foot care. The study highlights the vital role of foot care in enhancing postural control, with broader implications for aging population well-being and safety.

A multidisciplinary approach to managing lymphorroea in primary lymphoedema: a case study.

This case study describes the successful management of a patient with primary lymphoedema, who was experiencing lymphorrhoea and epidermolysis, using a multidisciplinary approach. The patient had Klippel-Trenaunay syndrome. The multidisciplinary team, in an outpatient clinic in Japan, included a certified lymphoedema therapist, plastic surgeons, and a wound, ostomy and continence nurse. The team performed complex physical therapy and lymphaticovenular anastomosis, which promoted the resolution of the lymphorrhoea. This resulted in improvements in skin condition, the prevention of recurrent cellulitis, and no increase in limb circumferences during the 1-year follow-up period. This report highlights the importance of a multidisciplinary approach to lymphoedema management, including lymphorrhoea control that fitted in with the patient's daily life. It is hoped that this article will contribute to the improvement of the quality of life of patients with lymphoedema.

513 - Blockage of IL-25 pathway as a potential target therapy for atopic dermatitis

Abstract Introduction Interleukin 25 (IL-25) is an alarmin that binds to its receptor composed of IL-17RA and IL-17RB and is known to induce the production of type 2 cytokines, leading to T helper type 2 (Th2) inflammatory responses. Atopic dermatitis (AD) is an autoimmune and chronic disorder that causes inflammation, dryness, redness and irritation of the skin. It is well-­documented that upregulated IL-25 expression is tightly correlated with the disease severity of AD patients, suggesting that the IL-25 pathway is a potential therapeutic target of AD. SM17 is a humanized antibody of the IgG4/kappa isotype targeting the IL-25 pathway via specific binding to IL-17RB, a co-receptor for IL-25 expressed on the surface of ILC2 cells, dendritic Cells, fibroblast and epithelial cells. Therefore, we hypothesize that SM17 might serve as a potential therapeutic treatment for AD. Objectives The current study aims at investigating if blockage of IL-25 pathway through SM17 administration could ameliorate AD associated inflammation, skin pathology and pruritus. Methods To provide first evidence that SM17 could improve skin conditions, PBMCs from healthy individuals were pretreated with a cocktail of alarmins comprising IL-25, IL-33, and TSLP with or without SM17, and the mixture was co-cultured with the fully differentiated human keratinocyte cell line HaCaT in a transwell system for five days. Filaggrin level in HaCaT cells was used as an indicator for skin health. Beneficial effects of SM17 in AD was further tested in the 1-Fluoro-2,4-dinitrobenzene (DNFB) induced AD mouse model. DNFB and SM17 were administrated to the animals once per week and tissues were harvested after a month. Single cells were isolated from submental lymph nodes for ex-vivo culture while both dorsal skin and ear were collected for histological and biochemical analyses. In vivo efficacy of SM17 was further compared with upadacitinib, a JAK1 inhibitor currently approved by the FDA for the treatments of adults and adolescents aged 12+ years with moderate to severe AD, via behavioral, histological and biochemical analyses. Results We first demonstrated that SM17 could potentially ameliorate the skin condition by upregulating the filaggrin levels in keratinocyte during Th2 inflammatory responses in vitro. In the DNFB induced AD mouse model, SM17 could improve the skin conditions in both ear and dorsal skin through attenuation of Th2 cytokine levels in submental lymph node and skin samples, and reduce infiltration of mast cell and eosinophil, while upregulating filaggrin expression in the skin layer. Weekly administration of SM17 provided similar efficacy as upadacitinib (5 doses/week) to suppress DNFB induced scratching behavior, thickening of skin and ear, and global induction of Th2 inflammatory responses in multiple tissues. Conclusions In summary, these in vitro and in vivo data indicate that blockade of IL-25 pathway by SM17 could suppress Th2 mediated inflammatory response and ameliorate the AD pathology similar to that of upadacitinib, probably with a superior safety profile as demonstrated in our Phase I clinical trial (ClinicalTrials.gov Identifier: NCT05332834), where good safety profile and tolerability were observed with no reported cases of severe TEAE. We believe that SM17 could serve as a potential therapeutic treatment for AD in the future.